New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 5, 2014
09:18 EDTSWHC, AVAV, NLSN, CSIQ, VEEV, THRM, YONG, NAVB, USU, XOMA, IMRSOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Smith & Wesson (SWHC), up 10%... AeroVironment (AVAV), up 7%... Gentherm (THRM), up 4%... Veeva (VEEV), up 5%. ALSO HIGHER: Dara (DARA), up 19% after signing agreement with WellCare (WCG) for Soltamox formulary status... Navidea (NAVB), up 3.7% after announcing FDA accepts sNDA to further expand Lymphoseek labeling. DOWN AFTER EARNINGS: Canadian Solar (CSIQ), down 5.4%... IMRIS (IMRS), down 3%. ALSO LOWER: XOMA (XOMA), down 21% after Phase II trial failure of gevokizumab in Erosive Osteoarthritis of the Hand... USEC (USU), down 29% after implementing financial restructuring plan under Chapter 11... Yongye (YONG), down 13% after announcing going private proposal not approved by stockholders...Nielsen (NLSN), down 2% after 30M share spot secondary offering of stock priced at $46.45.
News For SWHC;XOMA;USU;NAVB;YONG;THRM;VEEV;CSIQ;NLSN;AVAV;IMRS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
September 26, 2014
08:50 EDTCSIQSolar module prices rose in China, says Northland
After conducting checks, Northland believes that solar module prices in China have risen further in the past week and a half. The firm reports that solar module prices rose to 57c-58c in the last week and a half, up from 55c-56c in early September. The firm identifies China Solar (CSIQ) and JA Solar (JASO) as its favorite names in the sector. It has Outperform ratings on both names.
07:29 EDTNAVBNavidea announces CHMP adopts 'positive opinion' for Lymphoseek
Subscribe for More Information
06:47 EDTAVAVFAA drone decision could be milestone, NY Times says
Subscribe for More Information
September 24, 2014
09:55 EDTAVAVAeroVironment reports $22M order from Marine Corps
Subscribe for More Information
08:53 EDTCSIQCanadian Solar, JA Solar, and SunPower remain top picks at Northland
Subscribe for More Information
08:19 EDTIMRSIMRIS enters into waiver and amendment agreement and repricing of warrants
Subscribe for More Information
September 23, 2014
09:31 EDTNLSNSimulmedia and Nielsen announce development agreement
Simulmedia and Nielsen announced they have signed a development agreement to research "long tail" TV network measurement. This joint research will seek to capture the sizable audience activity that goes unmeasured today on niche cable networks. The agreement is the culmination of more than a year of joint research involving the Nielsen People Meter panel and Simulmedia's set-top box viewing data representing 50M viewers.
08:36 EDTCSIQCanadian Solar price target raised to $48 from $44 at Canaccord
Subscribe for More Information
07:31 EDTNAVBNavidea awarded $1.67M fast track NIH SBIR grant for evaluation of Lymphoseek
Navidea Biopharmaceuticals announced the receipt of an initial notice of award for a Fast Track Small Business Innovation Research grant providing for up to $1.67M from the National Cancer Institute, National Institutes of Health, to fund evaluation of Lymphoseek Injection in women with cervical cancer. The multicenter, clinical study in patients with early cervical cancer will seek to assess and provide data in support of the use of Lymphoseek in sentinel lymph node biopsy procedures which identify and evaluate the lymph nodes most likely to harbor additional cancer. The SBIR grant is awarded in two parts with the potential for total grant money up to a total of $1.67M over two and a half years. The first six-month funding segment of $165,917, which has already been awarded, is expected to enable Navidea to identify and qualify trial sites and secure necessary contracts and Institutional Review Board approvals. The second funding segment could provide for up to an additional $1.5M to be used to accrue participants; perform the sentinel lymph node procedures and pathology evaluations; and perform data analyses to confirm the safety and effectiveness of Lymphoseek. This study is designed as a multicenter, open-label, within-patient comparative study of Lymphoseek and an alternative lymphatic mapping agent referred to as vital blue dye for detection of lymph nodes in patients with cervical cancer. The study, using lymphatic mapping and SLN biopsy procedures, will compare the abilities of Lymphoseek and the alternative agent to identify SLNs during cervical cancer surgery. Additionally, the sentinel node pathology will be contrasted between agents and between the pathology of other nodes that may be removed during the procedure. The study is expected to involve 40 patients and last 1.5 years.
05:30 EDTCSIQCanadian Solar energises first PV plant at Shibushichocho
Canadian Solar announced the completion of the 1.2 MW solar PV power plant at Shibushichocho, Kagoshima Prefecture in Japan. Powered by Canadian Solar CS6P-255P modules, the plant will generate approximately 1,533MWh of clean, emission-less solar electricity per year. The electricity generated from the project will be purchased by Kyushu Electric Power Co., Inc. under a 20 year feed-in-tariff contract at the rate of 37c per kWh.
September 22, 2014
10:16 EDTVEEVOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:25 EDTTHRMCitigroup to hold a conference
Industrials Conference to be held in Boston on September 22-24.
07:10 EDTVEEVVeeva initiated with an Outperform at William Blair
Subscribe for More Information
September 19, 2014
06:41 EDTCSIQGlobal solar cell demand in 2014 estimated at 40GWp, DigiTimes says
Taiwan-based makers expect global solar cell demand in 2014 is estimated at 40GWp, reports DigiTimes. Of that amount, 11GWp will be in China, 8GWp in Europe, 7GWp in Japan, 5GWp in US and 1.3GWp in India. According to the sources, China- and Taiwan-based makers together have a total annual capacity of 39-42GWp in 2014, enough to meet global demand. Publicly traded companies in the space include Canadian Solar (CSIQ), First Solar (FSLR), JA Solar (JASO), SunPower (SPWR), Trina Solar (TSL) and Yingli Green Energy (YGE). Reference Link
September 18, 2014
18:25 EDTNAVBOn The Fly: After Hours Movers
HIGHER: Concur (CNQR), up 19.5% after SAP (SAP) announced that it will acquire the company for $129 per share... Navidea Biopharmaceuticals (NAVB), up 9.8% after confirming FDA orphan designation for Lymphoseek... Molycorp (MCP), up 6.1% after Oaktree Capital reported a 9.1% passive stake in the company... JetBlue (JBLU), up 4.6% following CEO transition announcement... Wendy's (WEN), up 2.15% after Trian reported a 24.39% stake in the company... Sears Holdings (SHLD), up 2.6% after Fairholme Capital reported a 24% stake in the company... AMD (AMD), up 1% after announcing that it expanded an IP partnership with Synopsys (SNPS). DOWN AFTER EARNINGS: Red Hat (RHT), down 3%... Oracle (ORCL), down 2.4% following first quarter earnings miss and CEO transition... Tibco Software (TIBX), down 5.5%. ALSO LOWER: Quest Resource (QRHC), down 13.4% after filing an automatic common stock and warrant shelf... Eagle Rock (EROC), down 4.5% after filing to sell 53.34M common units for limited partners... Chatham Lodging (CLDT), down 3.3% after filing to sell 5M shares of common stock... Glu Mobile (GLUU), down 2.3% after filing to sell 9.98M shares of common stock for holders... Blackstone Mortgage (BXMT), down 1.6% after filing to sell 8M shares of common stock.
16:10 EDTNAVBNavidea confirms FDA orphan designation for Lymphoseek in head, neck cancers
Subscribe for More Information
11:07 EDTNAVBNavidea granted orphan status for tilmanocept injection
Subscribe for More Information
07:23 EDTIMRSCraig-Hallum to hold a conference
Subscribe for More Information
07:21 EDTCSIQSolarbuzz: Five APAC markets to have 60% of solar PV demand, DigiTimes says
Subscribe for More Information
07:11 EDTUSUUSEC sets effective date for emergence from Chapter 11
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use